MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from maturity of
held-to-maturity securities
$237,500K
Net cash provided by
(used in) investing...
$13,799K
Canceled cashflow
$223,701K
Net (decrease)
increase in cash, cash...
-$100,702K
Canceled cashflow
$13,799K
Proceeds from exercise of
options
$1,511K
Net income
$447,179K
Noncash stock
compensation expense
$64,670K
Increase in accounts
payable and accrued...
$55,878K
Increase in deferred
revenue
$6,390K
Change in inventory
reserve
$6,171K
Noncash change in lease
liability and right of use...
$1,748K
Amortization of debt issuance
costs
$1,216K
Change in fair value of
equity investments
-$298K
Amortization of leasehold
interest
$185K
Depreciation and
amortization
$59K
Change in fair value of
notes payable
-$27K
Investment in
held-to-maturity securities
$222,237K
Investment in equity
investments
$1,250K
Purchases of property,
plant and equipment
$214K
Net cash (used in)
provided by financing...
-$89,729K
Net cash used in
operating activities
-$24,772K
Canceled cashflow
$1,511K
Canceled cashflow
$583,821K
Purchase of treasury
stock
$91,240K
Deferred income taxes
-$348,000K
Increase in accounts
receivable
$176,443K
Increase in other current
assets
$42,430K
Increase in inventory
$33,452K
Amortization of discount on
investment securities
$3,788K
(decrease) increase in
other current...
-$2,381K
Decrease in lease
liabilities
-$2,099K
Back
Back
Cash Flow
source: myfinsight.com
TG Therapeutics BRIUMVI Approval Call Slide Deck 12
TG THERAPEUTICS, INC. (TGTX)
TG Therapeutics BRIUMVI Approval Call Slide Deck 12
TG THERAPEUTICS, INC. (TGTX)